146307-51-9

Usage

Uses

Used in Organic Synthesis:
Methyl trans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate is utilized as a building block in organic synthesis for the creation of complex organic molecules. Its ability to participate in a range of chemical reactions, including esterification, amidation, and deprotection, makes it a versatile component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Drug Development:
In the pharmaceutical industry, Methyl trans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate serves as an intermediate in the development of new drugs. Its protected amine group allows for the controlled formation of amide bonds, which are crucial in the synthesis of peptide-based drugs and other bioactive molecules. Methyl trans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate's stability and reactivity make it an ideal candidate for the production of drug candidates with potential therapeutic applications.
Used in Chemical Research:
Methyl trans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate is also employed in chemical research as a model compound for studying reaction mechanisms and exploring new synthetic methodologies. Its predictable reactivity and the ease with which it can be modified make it a valuable tool for understanding the fundamental principles of organic chemistry and for developing innovative approaches to chemical synthesis.
Used in Specialty Chemicals Production:
Methyl trans-4-(tert-butoxycarbonylamino)cyclohexanecarboxylate finds application in the production of specialty chemicals, where its unique structural features can be exploited to create compounds with specific properties. These specialty chemicals may have applications in various industries, such as coatings, adhesives, and materials science, where tailored properties are required for specific uses.

Upstream product

• 67-56-1 methanol 
• 53292-90-3 trans-4-(tert-butoxycarbonylamino)cyclohexanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62456-15-9 methyl trans-4-amino-cyclohexanecarboxylate 
• 61367-07-5 trans-4-aminocyclohexylcarboxylic acid methyl ester hydrochloride 
• 34619-03-9 di-tert-butyl dicarbonate 
• 201230-82-2 carbon monoxide 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 74-88-4 methyl iodide 
• 27960-59-4 trans-4-aminocyclohexanecarboxylic acid hydrochloric acid 
• 128699-69-4 C₉H₁₅NO₄ 
• 75-65-0 tert-butyl alcohol 
• 600133-26-4 C₇H₈O₃S*C₈H₁₅NO₂ 

Downstream Products

• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 61367-07-5 trans-4-aminocyclohexylcarboxylic acid methyl ester hydrochloride 
• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 1207529-80-3 {(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl trifluoromethanesulfonate 
• 1319743-42-4 trans-N-[4-(3,3-dimethyl-2-oxo-2,3-dihydro-indol-1-ylmethyl)-cyclohexyl]-4-fluoro-3-trifluoromethyl-benzamide 
• 1319743-51-5 trans-1-(4-amino-cyclohexylmethyl)-3,3-dimethyl-1,3-dihydro-indol-2-one 
• 146447-21-4 trans-methyl 4-(methylamino)cyclohexanecarboxylate hydrochloride 
• 62456-15-9 methyl trans-4-amino-cyclohexanecarboxylate 
• 181308-57-6 trans-(4-formyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 506427-91-4 trans N-tert-butoxycarbonyl-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]ethyl}-cyclohexylamine 
• 791778-53-5 trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexane-1-amine 
• 215790-29-7 trans-2-(1-(4-(N-tert-butoxycarbonyl)amino)cyclohexyl)acetaldehyde 

Relevant academic research and scientific papers

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat

D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine

Functionally selective G protein-coupled receptor ligands are valuable tools for deciphering the roles of downstream signaling pathways that potentially contribute to therapeutic effects versus side effects. Recently, we discovered both Gi/o-bi

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Copper-Catalyzed and Indium-Mediated Methoxycarbonylation of Unactivated Alkyl Iodides with Balloon CO

This work emphasizes the synthesis of alkyl esters via Cu-catalyzed and In-mediated alkoxycarbonylation of unactivated alkyl iodides in the presence of In or InI. The reactions were suitable for the preparation of primary, secondary, and even tertiary alkyl esters, representing an exceptionally rare example for the creation of quaternary carbon centers upon formation of esters. The preliminary mechanistic studies indicated that alkyl radicals were involved, and Cu/In/CO played a cooperative role in the carbonylation event.

NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF

The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic di

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo

Since the demonstration of nicotine vaccines as a possible therapeutic intervention for the effects of tobacco smoke, extensive effort has been made to enhance nicotine specific immunity. Linker modifications of nicotine haptens have been a focal point for improving the immunogenicity of nicotine, in which the evaluation of these modifications usually relies on in vivo animal models, such as mice, rats or nonhuman primates. Here, we present two in vitro screening strategies to estimate and predict the immunogenic potential of our newly designed nicotine haptens. One utilizes a competition enzyme-linked immunoabsorbent assay (ELISA) to profile the interactions of nicotine haptens or hapten-protein conjugates with nicotine specific antibodies, both polyclonal and monoclonal. Another relies on computational modeling of the interactions between haptens and amino acid residues near the conjugation site of the carrier protein to infer linker-carrier protein conjugation effect on antinicotine antibody response. Using these two in vitro methods, we ranked the haptens with different linkers for their potential as viable vaccine candidates. The ELISA-based hapten ranking was in an agreement with the results obtained by in vivo nicotine pharmacokinetic analysis. A correlation was found between the average binding affinity (IC50) of the haptens to an anti-Nic monoclonal antibody and the average brain nicotine concentration in the immunized mice. The computational modeling of hapten and carrier protein interactions helps exclude conjugates with strong linker-carrier conjugation effects and low in vivo efficacy. The simplicity of these in vitro screening strategies should facilitate the selection and development of more effective nicotine conjugate vaccines. In addition, these data highlight a previously under-appreciated contribution of linkers and hapten-protein conjugations to conjugate vaccine immunogenicity by virtue of their inclusion in the epitope that binds and activates B cells.

ATX MODULATING AGENTS

Compounds of formula (I) can modulate the activity of autotaxin (ATX).